AMEX:STXS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Stereotaxis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: STXS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.5%

STXS

0.2%

US Medical Equipment

2.5%

US Market


1 Year Return

61.3%

STXS

15.4%

US Medical Equipment

16.3%

US Market

Return vs Industry: STXS exceeded the US Medical Equipment industry which returned 14.8% over the past year.

Return vs Market: STXS exceeded the US Market which returned 15.8% over the past year.


Shareholder returns

STXSIndustryMarket
7 Day0.5%0.2%2.5%
30 Day-8.3%8.9%5.6%
90 Day-1.0%11.1%16.4%
1 Year61.3%61.3%16.4%15.4%18.8%16.3%
3 Year585.0%585.0%77.0%72.3%45.1%35.7%
5 Year320.7%320.7%120.4%103.3%75.8%56.8%

Price Volatility Vs. Market

How volatile is Stereotaxis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Stereotaxis undervalued compared to its fair value and its price relative to the market?

7.92x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate STXS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate STXS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: STXS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: STXS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STXS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STXS is overvalued based on its PB Ratio (7.9x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Stereotaxis forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

19.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STXS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STXS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STXS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STXS's revenue (33.7% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: STXS's revenue (33.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if STXS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Stereotaxis performed over the past 5 years?

9.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: STXS is currently unprofitable.

Growing Profit Margin: STXS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STXS is unprofitable, but has reduced losses over the past 5 years at a rate of 9.2% per year.

Accelerating Growth: Unable to compare STXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.7%).


Return on Equity

High ROE: STXS has a negative Return on Equity (-11.93%), as it is currently unprofitable.


Next Steps

Financial Health

How is Stereotaxis's financial position?


Financial Position Analysis

Short Term Liabilities: STXS's short term assets ($53.2M) exceed its short term liabilities ($13.9M).

Long Term Liabilities: STXS's short term assets ($53.2M) exceed its long term liabilities ($1.8M).


Debt to Equity History and Analysis

Debt Level: STXS's debt to equity ratio (5.2%) is considered satisfactory.

Reducing Debt: STXS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STXS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: STXS has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 17.4% each year


Next Steps

Dividend

What is Stereotaxis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate STXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STXS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STXS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average board tenure


CEO

David Fischel (33 yo)

3.5yrs

Tenure

US$240,300

Compensation

Mr. David Leo Fischel, CPA, CFA, CAIA, MBA, has been the Chairman and Chief Executive Officer of Stereotaxis, Inc. since February 3, 2017. Mr. Fischel is a Principal and primary portfolio manager for medic ...


Board Members

NamePositionTenureCompensationOwnership
David Fischel
CEO & Chairman3.5yrsUS$240.30k0.029%
$ 77.4k
Arun Menawat
Independent Director3.92yrsUS$240.30k0.48%
$ 1.3m
Joseph Kiani
Independent Director3.92yrsUS$240.30k8.94%
$ 23.9m
Robert Messey
Independent Director15.25yrsUS$240.30k0.17%
$ 448.2k
Nathan Fischel
Director3.5yrsUS$240.30k0.029%
$ 77.4k
David Benfer
Lead Independent Director5.5yrsUS$240.30k0.36%
$ 970.0k
Ross Levin
Independent Director2.17yrsUS$240.30kno data

3.9yrs

Average Tenure

64yo

Average Age

Experienced Board: STXS's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.


Top Shareholders

Company Information

Stereotaxis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Stereotaxis, Inc.
  • Ticker: STXS
  • Exchange: AMEX
  • Founded: 1990
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$267.157m
  • Shares outstanding: 69.03m
  • Website: https://www.stereotaxis.com

Number of Employees


Location

  • Stereotaxis, Inc.
  • 4320 Forest Park Avenue
  • Suite 100
  • St. Louis
  • Missouri
  • 63108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STXSAMEX (NYSE MKT LLC)YesCommon SharesUSUSDAug 2004

Biography

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/08 00:04
End of Day Share Price2020/08/07 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.